Mersana therapeutics, inc. (MRSN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities
Net income (loss)

-16,926

-16,246

-16,792

-17,071

21,901

-22,432

-17,069

-12,353

-12,403

-13,967

-7,732

-8,947

-8,061

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation

248

282

310

316

337

350

342

307

258

255

235

229

209

Loss on disposal of fixed assets

-

-

-

-

-

0

0

0

-20

-

-

-

-

Net amortization of premiums and discounts on investments

66

135

78

13

-4

8

40

91

157

-

-

-

-

Stock-based compensation

1,609

1,262

1,285

1,161

1,164

1,128

1,053

958

745

432

373

353

264

Non-cash rent expense

-

-

-

-

-

-

21

43

13

-

-

-

-

Change in deferred rent

-

-

-

-

-

-

-

-

-

-44

-44

-43

-28

Other non-cash items

-37

-

-

-

-26

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-

-298

10

-180

9

-127

-1,095

1,393

-496

53

218

-199

-339

Prepaid expenses and other current assets

330

-861

-1,854

925

-389

311

-591

884

1,086

-591

865

417

509

Other assets

-

-

-

-

-

-301

0

0

1,433

-13

-470

-602

1,025

Accounts payable

-2,693

-8

814

-472

-3,444

3,756

2,643

1,593

-617

223

1,317

-152

-53

Accrued expenses

-3,128

949

-2,824

2,769

-4,463

1,863

2,191

2,626

-1,249

2,430

64

479

589

Operating lease assets

-444

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-430

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-11

169

-835

-123

-40,592

-711

-1,301

-2,254

-1,977

-701

-4,566

-1,992

-2,635

Net cash used in operating activities

-21,246

-12,576

-16,284

-14,197

-24,687

-15,904

-10,474

-11,448

-17,390

-10,996

-11,084

-9,689

-10,910

Cash flows from investing activities
Maturities of marketable securities

19,500

16,500

0

0

10,500

14,000

21,000

30,400

23,165

-

-

-

-

Purchase of property and equipment

65

0

27

206

372

277

273

553

267

710

105

-143

471

Net cash provided by investing activities

19,435

16,500

-41,768

-12,153

10,128

13,723

20,727

29,847

22,898

-13,190

-41,854

-44,109

-471

Cash flows from financing activities
Net proceeds from offering of common stock

-

0

0

0

92,162

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

119

54

21

58

42

65

128

470

255

21

67

260

104

Payments from issuance of debt

180

-

-

-

-

-

-

-

-

-

-

-

-

Payments under capital lease obligations

29

-

-

-

-

-

-

-

-

-

-

-

-

Payments of financing costs

-

-

-

-

-

-

-

-

-

-

-

1,924

505

Net cash provided by (used in) financing activities

-90

231

-8

5,277

92,204

211

209

389

255

21

70,641

-1,664

-401

Increase (decrease) in cash, cash equivalents and restricted cash

-1,901

4,155

-58,060

-21,073

77,645

-1,970

10,462

18,788

5,763

-24,165

17,703

-55,462

-11,782

Supplemental disclosures of non-cash activities:
Purchases of property and equipment in accounts payable and accrued expenses

-

-

-

0

26

242

-159

-86

320

-

-

-

154

Cash paid for interest

56

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for operating lease liabilities

9,980

-

-

-

4,369

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for financing lease liabilities

-

-

-

-

429

-

-

-

-

-

-

-

-

Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606

-

-

-

-

-

0

0

0

-2,031

-

-

-

-